BG102781A - Изолиран димерен фибробласт-активиращ протеин алфа и неговото използване - Google Patents

Изолиран димерен фибробласт-активиращ протеин алфа и неговото използване

Info

Publication number
BG102781A
BG102781A BG102781A BG10278198A BG102781A BG 102781 A BG102781 A BG 102781A BG 102781 A BG102781 A BG 102781A BG 10278198 A BG10278198 A BG 10278198A BG 102781 A BG102781 A BG 102781A
Authority
BG
Bulgaria
Prior art keywords
application
fibroblastactivation
protein alpha
isolated dimer
dimer
Prior art date
Application number
BG102781A
Other languages
English (en)
Inventor
Rainer Zimmerman
John Park
Wolfgang Rettig
Lloyd Old
Original Assignee
Ludwig Institute For Cancer Research
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute For Cancer Research, Boehringer Ingelheim International Gmbh filed Critical Ludwig Institute For Cancer Research
Publication of BG102781A publication Critical patent/BG102781A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)

Abstract

Изобретението се отнася до димерни форми на протеин, известен като фибробластактивиращ протеин или FAP , и до неговото използване.
BG102781A 1996-03-18 1998-09-18 Изолиран димерен фибробласт-активиращ протеин алфа и неговото използване BG102781A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/619,280 US5767242A (en) 1994-04-20 1996-03-18 Isolated dimeric fibroblast activation protein alpha, and uses thereof
PCT/US1997/004215 WO1997034927A1 (en) 1996-03-18 1997-03-12 Isolated dimeric fibroblast activation protein alpha, and uses thereof

Publications (1)

Publication Number Publication Date
BG102781A true BG102781A (bg) 1999-09-30

Family

ID=24481231

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102781A BG102781A (bg) 1996-03-18 1998-09-18 Изолиран димерен фибробласт-активиращ протеин алфа и неговото използване

Country Status (23)

Country Link
US (2) US5767242A (bg)
EP (1) EP0960127B1 (bg)
JP (1) JP4102441B2 (bg)
KR (1) KR20000064655A (bg)
CN (1) CN1214052A (bg)
AT (1) ATE449106T1 (bg)
AU (1) AU729369B2 (bg)
BG (1) BG102781A (bg)
BR (1) BR9708100A (bg)
CA (1) CA2242342C (bg)
CZ (1) CZ299698A3 (bg)
DE (1) DE69739665D1 (bg)
DK (1) DK0960127T3 (bg)
EE (1) EE03693B1 (bg)
ES (1) ES2334183T3 (bg)
HU (1) HUP0104468A3 (bg)
IL (1) IL125124A0 (bg)
NO (1) NO984298L (bg)
NZ (2) NZ331758A (bg)
PL (1) PL328947A1 (bg)
SK (1) SK126798A3 (bg)
TR (1) TR199801845T2 (bg)
WO (1) WO1997034927A1 (bg)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455677B1 (en) 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
US6979697B1 (en) * 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
EP1806138A1 (en) * 1999-05-25 2007-07-11 Point Therapeutics, Inc. Anti-tumor agents comprising boroproline compounds
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
CA2373643A1 (en) * 1999-05-25 2000-11-30 Point Therapeutics, Inc. Anti-tumor comprising boroproline compounds
US20030092890A1 (en) * 1999-07-28 2003-05-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2005508838A (ja) * 2001-03-23 2005-04-07 アフトン コーポレーション 膵癌の組合せ治療
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
AU2002326356A1 (en) * 2001-07-09 2003-01-29 Aphton Corporation Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
CA2484551A1 (en) 2002-04-30 2003-11-13 Trustees Of Tufts College Smart pro-drugs of serine protease inhibitors
AU2003248921A1 (en) * 2002-07-09 2004-01-23 Point Therapeutics, Inc. Boroproline compound combination therapy
US7309774B2 (en) 2003-02-07 2007-12-18 The Board Of Regents Of The University Of Oklahoma Antiplasmin cleaving enzyme
US20080057491A1 (en) * 2003-02-07 2008-03-06 Mckee Patrick A Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use
US20060020119A1 (en) * 2004-03-29 2006-01-26 Stephen Grimes Monoclonal antibodies to gastrin hormone
WO2004088326A2 (en) * 2003-03-28 2004-10-14 Aphton Corporation Gastrin hormone immunoassays
WO2005071073A1 (en) * 2004-01-09 2005-08-04 Point Therapeutics, Inc. Fap compositions and the use thereof for immunomodulation
EP1784645A2 (en) * 2004-07-29 2007-05-16 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with fibroblast activation protein
EP1794586B1 (en) 2004-09-22 2013-01-30 Cancer Advances, Inc., Monoclonal antibodies to progastrin
US20090238862A1 (en) * 2004-10-27 2009-09-24 Wen-Tien Chen Methods and Compositions for Seprase Inactivation
ES2564169T3 (es) 2004-11-24 2016-03-18 Techlab, Inc. Dispositivo y método para la detección de analitos
EP1963537A4 (en) 2005-12-14 2009-11-11 Ludwig Inst For Cancer Res Ltd METHOD FOR DIAGNOSING RHEUMATOID ARTHRITIS BY TESTING MYOFIBROBLASTIC-SIMILAR SYNOVOCYTES FOR A FIBROBLAST ACTIVATION PROTEIN
US8933201B2 (en) 2006-06-07 2015-01-13 The Board Of Regents Of The University Of Oklahoma Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
CA2657217A1 (en) * 2006-06-21 2007-12-27 The Scripps Research Institute Dna composition against tumor stromal antigen fap and methods of use thereof
US8513187B2 (en) 2009-02-27 2013-08-20 Trustees Of Tufts College Soft protease inhibitors, and pro-soft forms thereof
JP6523965B2 (ja) 2012-12-28 2019-06-05 コビオレス エヌヴイＣｏｂｉｏｒｅｓ Ｎｖ 最小毒性プロドラッグ
CN103267852B (zh) * 2013-05-15 2015-03-25 中国医学科学院北京协和医院 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
WO2015192123A1 (en) 2014-06-13 2015-12-17 Trustees Of Tufts College Fap-activated therapeutic agents, and uses related thereto
CN105859866B (zh) * 2016-05-27 2019-08-13 郑州大学 Fap来源的抗肿瘤ctl表位肽p265及其应用
US20200237936A1 (en) 2016-12-14 2020-07-30 Purdue Research Foundation Fibroblast activation protein (fap)-targeted imaging and therapy
KR102772810B1 (ko) 2017-06-15 2025-02-28 캔서 어드밴시스 아이엔씨 종양 및 암에 대한 체액성 및 세포 면역을 유도하기 위한 조성물 및 방법
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
CN116635054A (zh) 2020-12-22 2023-08-22 科比欧尔斯公司 包括四肽部分的化合物
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1320734C (en) * 1986-02-04 1993-07-27 Suntory Limited Pyrrolidineamide derivative of acylamino acid and pharmaceutical composition containing the same
US5587299A (en) * 1994-04-20 1996-12-24 Memorial Sloan-Kettering Cancer Center Isolated nucleic acid molecule coding for fibroblast activation protein alpha and uses thereof

Also Published As

Publication number Publication date
JP4102441B2 (ja) 2008-06-18
EP0960127A4 (en) 2004-09-08
EE03693B1 (et) 2002-04-15
EE9800306A (et) 1999-02-15
US5767242A (en) 1998-06-16
HUP0104468A2 (hu) 2002-04-29
BR9708100A (pt) 2000-01-04
AU2330297A (en) 1997-10-10
IL125124A0 (en) 1999-01-26
DE69739665D1 (de) 2009-12-31
AU729369B2 (en) 2001-02-01
ES2334183T3 (es) 2010-03-05
JP2000507100A (ja) 2000-06-13
NO984298D0 (no) 1998-09-17
CA2242342C (en) 2013-05-14
NZ331758A (en) 2000-01-28
NZ335543A (en) 2001-03-30
KR20000064655A (ko) 2000-11-06
ATE449106T1 (de) 2009-12-15
DK0960127T3 (da) 2010-03-29
CN1214052A (zh) 1999-04-14
EP0960127A1 (en) 1999-12-01
EP0960127B1 (en) 2009-11-18
PL328947A1 (en) 1999-03-01
CA2242342A1 (en) 1997-09-25
CZ299698A3 (cs) 1999-01-13
NO984298L (no) 1998-09-17
SK126798A3 (en) 1999-05-07
TR199801845T2 (xx) 1998-12-21
WO1997034927A1 (en) 1997-09-25
HUP0104468A3 (en) 2004-10-28
US5965373A (en) 1999-10-12

Similar Documents

Publication Publication Date Title
IL125124A0 (en) Dimeric forms of the protein fapalpha and uses thereof
NO964966D0 (no) Lactobacillusstammer av human opprinnelse, blandinger samt anvendelse derav
ES2195970T3 (es) L-ribavirina y usos de la misma.
YU15299A (sh) Farmaceutski sastavi
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
IL127918A0 (en) Novel amino sugar and related sugar derivatives of indolylopyrrolocarbazoles their use as antitumor agents and pharmaceutical formulations
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
AR016981A2 (es) Polipeptidos sinteticos
MX9204623A (es) Compuesto de bis-4-piperidil-fosfita n-metilada.
BG101787A (bg) Апротининови варианти с подобрени свойства
TR199900430T2 (xx) �kameli 1,2,3,4-tetrahidro-2-dibenzofuranaminler ve 2-aminosiklohepta$b] benzofuranlar.
MY127474A (en) Naphthyl compounds, intermediates, compositions, and methods of use
BG104373A (bg) Полиморфни форми на дофетилид
HUT73328A (en) Rye-flour
PE20399A1 (es) Muteina ob
BG102937A (bg) Зона пелуцида протеини като контрацептиви
AU7233296A (en) Streptoccal inhibitor of complement-mediated lysis, protein sic
ZA978233B (en) The use of protein as anti-retroviral agents.
MX9602767A (es) Dimaleato de n,n-dietil-8,8-dipropil-2-azaspiro[4,5]decano-2-propanamina.
FR2717391B1 (fr) Peptides pour inhiber la libération de pepsine.
IT1289633B1 (it) Composizione e procedimento per la fabbricazione di manufatti cementizi.
MX9800981A (es) Promotor del gen de endoglina humana y su uso.
MX9702231A (es) Nuevos trimeros de isocianato y mezclas de trimeros de isocianato, su obtencion y empleo.
ES1032970Y (es) Cuerpo recreativo de poliedros.
ITFE930013U1 (it) Bacchette orientali meccanizzate.